BrainRepair UG

The future of BrainRepair is now !

• We are the founders of BrainRepair UG (https://brainrepair.eu/)
• We are a German Start-up with EMA SME Qualification EMA/SME/357/15/R3
• We develop autologous (own) cord blood stem cell therapies in Europe/USA for the treatment of Pediatric brain injury
• Our product was granted ATMP-TEP Classification by EMA for Pediatric brain damage, hypoxic-ischemic encephalopathy, and cerebral palsy.

• We develop and market (own) cord blood stem cell treatments for
• The treatment of Pediatric brain injury
  • Periventricular leukomalacia
  • Neonatal encephalopathy
  • Perinatal intracranial hemorrhage
  • Pediatric stroke
  • Cerebral palsy
  • TBI
  • SCI

What makes us unique?

• Worldwide first Orphan Drug Designation granted by the European Commission/EMA on October 14, 2016 for
• ‘Autologous mononuclear cells derived from human cord blood’ for the treatment of newborns suffering from:
  • Periventricular leukomalacia (EU/3/16/1744)
  • Neonatal encephalopathy (EU/3/16/1743)
• First successful autologous cell therapy of Cerebral palsy and coma in 2009 (Jensen et al., 2009; 2011; 2013)
  http://dx.doi.org/10.1155/2013/951827
• First successful autologous cell therapy of Perinatal ischemic stroke during birth (Jensen and Hamelmann, 2016)
  http://dx.doi.org/10.1155/2016/1717426
• First pre-clinical prevention of ‘spastic paresis’ in newborn rats after cerebral hypoxic-ischemia (Meier et al., 2006)
  https://www.researchgate.net/publication/7333251